223 related articles for article (PubMed ID: 25008066)
1. Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications.
Przybyl J; Kozak K; Kosela H; Falkowski S; Switaj T; Lugowska I; Szumera-Cieckiewicz A; Ptaszynski K; Grygalewicz B; Chechlinska M; Pienkowska-Grela B; Debiec-Rychter M; Siedlecki JA; Rutkowski P
Med Oncol; 2014 Aug; 31(8):109. PubMed ID: 25008066
[TBL] [Abstract][Full Text] [Related]
2. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS
Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587
[TBL] [Abstract][Full Text] [Related]
3. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
4. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
[TBL] [Abstract][Full Text] [Related]
5. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
[TBL] [Abstract][Full Text] [Related]
6. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
7. Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples.
de Alava E; Lozano MD; Patiño A; Sierrasesúmaga L; Pardo-Mindán FJ
Diagn Mol Pathol; 1998 Jun; 7(3):152-7. PubMed ID: 9836070
[TBL] [Abstract][Full Text] [Related]
8. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
Yuan B; Ji W; Xia H; Li J
Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
[TBL] [Abstract][Full Text] [Related]
10. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.
van Doorninck JA; Ji L; Schaub B; Shimada H; Wing MR; Krailo MD; Lessnick SL; Marina N; Triche TJ; Sposto R; Womer RB; Lawlor ER
J Clin Oncol; 2010 Apr; 28(12):1989-94. PubMed ID: 20308669
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
13. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Mackintosh C; Ordóñez JL; García-Domínguez DJ; Sevillano V; Llombart-Bosch A; Szuhai K; Scotlandi K; Alberghini M; Sciot R; Sinnaeve F; Hogendoorn PC; Picci P; Knuutila S; Dirksen U; Debiec-Rychter M; Schaefer KL; de Álava E
Oncogene; 2012 Mar; 31(10):1287-98. PubMed ID: 21822310
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and molecular spectrum of ewing sarcomas/PNETs, including validation of EWSR1 rearrangement by conventional and array FISH technique in certain cases.
Rekhi B; Vogel U; Basak R; Desai SB; Jambhekar NA
Pathol Oncol Res; 2014 Jul; 20(3):503-16. PubMed ID: 24293381
[TBL] [Abstract][Full Text] [Related]
16. Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior.
Tsuda Y; Dickson BC; Swanson D; Sung YS; Zhang L; Meyers P; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2020 May; 59(5):286-294. PubMed ID: 31756779
[TBL] [Abstract][Full Text] [Related]
17. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
18. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
Jiménez JA; Apfelbaum AA; Hawkins AG; Svoboda LK; Kumar A; Ruiz RO; Garcia AX; Haarer E; Nwosu ZC; Bradin J; Purohit T; Chen D; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
Mol Cancer Res; 2021 Jul; 19(7):1182-1195. PubMed ID: 33741715
[TBL] [Abstract][Full Text] [Related]
19. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
20. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
